European Innovation Council

Limula Biotech is a Swiss company specializing in the design and development of an automated system for manufacturing cell and gene therapies. The company has created a patented platform that enables the distributed production of genetically engineered cells directly at the patient's bedside, utilizing a patient's white blood cell sample. This fully closed bioreactor system minimizes human intervention during the manufacturing process while maintaining control over cell culture parameters. By facilitating on-site production in hospitals, Limula's technology aims to enhance the safety, accessibility, and efficiency of personalized gene therapies, ultimately reducing time, costs, and logistical challenges. Founded in 2018 and based in Lausanne, Switzerland, Limula Biotech is committed to revolutionizing the delivery of ex vivo gene-engineered cell therapies.

Core Biogenesis is a biotechnology company building next-generation recombinant protein production technologies. The company uses proprietary gene editing and plant biotechnology to drastically reduce the cost of making growth factors. The growth factors are molecules used in the clean meat and cell therapy industries.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that serve as a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, focusing particularly on transcriptomics. By enabling single-cell barcoding in a test tube format, Scipio Bioscience's products facilitate advanced research in single-cell analysis, supporting laboratories in their scientific endeavors.

Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes Caenorhabditis elegans, a type of microscopic worm, for the assessment of substances in pharmaceutical, chemical, and cosmetic industries. This technology, known as "Organism-on-Chip," integrates in vivo testing with a fully automated in vitro platform for handling, culturing, and analyzing these organisms. Nagi Bioscience's solutions facilitate toxicity testing, drug discovery, and anthelmintic testing, allowing clients to gain insights into the complete biological responses that can only be observed at the organism level. This approach aims to transform traditional methods of evaluating the toxic or beneficial effects of various substances.

Xsensio develops the unique Lab-on-Skin™​ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way. The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developed at the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.

Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.

Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.

Genome Biologics are leaders in therapeutic target discovery and RNA-targeted therapies in cardiovascular and cardiometabolic disease. Our technology platforms seamlessly integrate synergistically to accelerate development of RNAi therapies to treat illnesses where no other treatments have proven effective or ever existed.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.

RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.

Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.

Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.

Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.

Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.

Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.

Ilya Pharma AB is a biotechnology company based in Uppsala, Sweden, that specializes in developing biological drugs aimed at treating wounds in skin and mucosa. Founded in 2016, the company focuses on addressing both acute and chronic wounds, particularly those affecting individuals with diabetes. Ilya Pharma employs a unique approach by genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that enhance the healing process of skin injuries. Their innovative drug delivery system utilizes these bacteria as vectors to administer biological drugs directly at the wound site or within the gastrointestinal tract, facilitating accelerated healing in a cost-effective manner. The company’s research and development efforts are rooted in extensive scientific studies conducted at Uppsala University and the Swedish University of Agriculture.

RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.

Xsensio develops the unique Lab-on-Skin™​ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way. The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developed at the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.

Xsensio develops the unique Lab-on-Skin™​ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way. The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developed at the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.

Biome Makers Inc. is a biotechnology company based in San Francisco, California, founded in 2015. The company specializes in understanding and identifying microbiomes, particularly in the context of agriculture. By utilizing DNA sequencing technologies and proprietary Intelligent Computing systems, Biome Makers provides detailed, crop-specific insights and recommendations to enhance agricultural production and product quality. Their technology enables growers and manufacturers to analyze soil ecosystems effectively, offering data-driven insights that facilitate improved decision-making in farming practices.

S-Biomedic is a Belgian biotech company specializing in live probiotic cosmetics designed to improve skin health. The company focuses on the skin microbiome, a complex ecosystem of beneficial and harmful bacteria that plays a crucial role in skin conditions such as acne, eczema, rosacea, and aging. S-Biomedic employs advanced modulation-based technology to selectively harness beneficial bacteria, creating products that promote the rebalancing of the skin microbiome. By utilizing the latest advancements in microbiology and dermatology, their offerings aim to restore healthy skin and address various dermatological concerns. Through this innovative approach, S-Biomedic provides therapeutic solutions in both the dermatology and cosmetic sectors, enhancing the overall health and beauty of the skin.